- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01223118
Evaluation of the Impact of Vitrification on Oocytes
Evaluation of the Impact of Vitrification on the Reproductive Performance and Potential of Human Oocytes
Studienübersicht
Detaillierte Beschreibung
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Cryopreservation of human oocytes has a great potential to preserve or extend fertility in the face of disease whose treatment would result in a loss of ovarian function. (malignancy, severe autoimmune disease, etc.). It would also provide a means of quarantining oocytes to be used in oocyte donation to provide the lowest possible risk of infection.
There are two methods for storage of oocytes: slow freezing or vitrification. Slow freezing is the conventional method and has been successfully used for embryos since 1983 and more recently for oocytes. Recent reports indicate that vitrification may be more successful than slow freezing. However, the technique has not been rigorously validated to date. The aim of this study is to determine the rate of cryosurvival of mature oocytes following vitrification, and to then compare the reproductive potential of vitrified oocytes relative to those which have not been cryopreserved.
Patients will undergo ovarian stimulation for in vitro fertilization (IVF) according to the protocol recommended by their primary doctor. After retrieval, mature oocytes will be divided in half. One half will undergo vitrification, immediate thaw and intracytoplasmic sperm injection (ICSI). The other half will undergo just ICSI. All embryos will then develop on identical culture until day 3 or day 5. Prior to transfer, the best embryo from each group will undergo biopsy for genetic fingerprinting. The patient will have a 2 embryo transfer (one from each group). All extra embryos will be biopsied for pre-implantation genetic diagnosis (PGD) prior to being cryopreserved. If the patient becomes pregnant, we will follow up with an additional blood draw at approximately 9 weeks gestation and buccal swabs after the delivery of the infant(s).
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Reproductive Medicine Associates of New Jersey
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18104
- Reproductive Medicine Assoicates of PA at Lehigh Valley
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
This study will recruit patients from the NY/NJ/CT/eastern PA area only.
Inclusion Criteria:
- No prior failed IVF treatment cycle
- Female partner less than 35 years of age at time of onset of the IVF cycle
- Normal maximum prior day 3 follicle stimulating hormone (FSH) level (< or = 10 IU/L)
- Total basal antral follicle count greater than or equal to 12
- Male partner with greater than 100,000 total motile spermatozoa Donor sperm is acceptable but the couples will be required to provide one additional vial for DNA analysis
- Body Mass Index (BMI) ≤ 32 kg/m2
Exclusion Criteria:
- Diagnosis of chronic oligoovulation or anovulation (cycle typically occurring less often than every 38 days)
- Diagnosis of endometrial insufficiency
- Clinical indication for PGD (undergoing IVF with PGD to rule out a known genetic defect)
- Use of testicular aspiration or biopsy procedures to obtain sperm
- Unevaluated ovarian mass
- Presence of hydrosalpinges which communicate with the endometrial cavity
- Any contraindication to undergoing in vitro fertilization or gonadotropin stimulation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Oocyte Vitrification
Each patient will have oocytes randomized into two groups immediately after retrieval.
Half of oocytes will be vitrified, thawed and inseminated.
The other half will be inseminated only.
All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups).
Following delivery, buccal swabs will be collected on all infants.
|
Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination.
All embryos will undergo biopsy for PGD prior to transfer.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Aneuploidy Rate (evaluation of whether embryo is chromosomally normal)
Zeitfenster: 1 year
|
Compare the rate of chromosomally-abnormal embryos among embryos originating from vitrified oocytes versus embryos originating from fresh/control oocytes.
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Delivery rates
Zeitfenster: 1 year
|
All embryos will be biopsied prior to transfer and DNA samples will be collected from all infants.
Compare embryonic and infant DNA to evaluate whether the live birth resulted from a vitrified or a fresh/control oocyte.
|
1 year
|
Paired Sustained Implantation Rate (number of viable fetuses beyond the first trimester per embryo transferred)
Zeitfenster: 1 year
|
Among patients with a paired two blastocyst transfer, compare the implantation rate of embryos originating from vitrified oocytes versus embryos originating from fresh/control oocytes.
|
1 year
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Richard T Scott, MD, Reproductive Medicine Associates of New Jersey
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- RMA-2010-02
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Vitrification and PGD
-
University of AarhusRekrutierung
-
Universitat Jaume IAbgeschlossen
-
University of OregonSpecial X Inc.RekrutierungEltern-Kind-Beziehungen | Erziehung | Verhalten von Kindern | Entwicklungsstörung | Entwicklungsverzögerung | Entwicklungsstörung, KindVereinigte Staaten
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)AbgeschlossenDemenz | Alzheimer Erkrankung | Familienmitglieder | Burnout der PflegekraftVereinigte Staaten
-
University of Southern CaliforniaAbgeschlossenSimulatorkrankheitVereinigte Staaten
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID); AIDS Healthcare...Abgeschlossen
-
University of South FloridaUnbekanntSchwangerschaftsverhütung bei TeenagernVereinigte Staaten
-
University of CincinnatiNational Institute of Nursing Research (NINR)RekrutierungStreicheln | FamilienbetreuerVereinigte Staaten
-
Dalarna UniversityUppsala University; The Swedish Research CouncilRekrutierungDemenz | Leichte kognitive Einschränkung | Demenz, gemischt | Demenz vom Alzheimer-Typ | Subjektive kognitive Beeinträchtigung | Demenz senilSchweden
-
hearX GroupUniversity of PretoriaAbgeschlossen